Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-3 targeted T cell therapy
- Development stage
- Unknown
- Lead developer
- Oncology Department of PLA General Hospital
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MAGE-3 targeted T cell therapy is an adoptive cellular immunotherapy designed to target cells expressing the Melanoma-associated antigen 3 (MAGE-A3). MAGE-A3 is a member of the cancer-testis antigen family, which is typically expressed in various malignant tumors but absent in normal adult tissues except for the testis and placenta, making it a highly specific target for cancer therapy. This specific therapeutic approach, developed by the Oncology Department of PLA General Hospital, involves the administration of T cells that have been primed or engineered to recognize MAGE-3 antigens. Once infused into the patient, these T cells identify and eliminate MAGE-3-positive tumor cells through cytotoxic mechanisms. The therapy is being evaluated for the treatment of advanced solid tumors in patients who have failed standard chemotherapy or targeted treatments.
- Other names
- MAGE-3 antigen / mutation specific antigen specific T cell targeted immunotherapyMAGE-3 specific T cell therapyMAGE3 specific T cell therapyMAGE 3 specific T cell therapy
02
Targets
MAGE-A3/HLA-I (Melanoma-associated antigen 3 peptide-HLA class I complex)
Beyond the preview
Go deeper on MAGE-3 targeted T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-3 targeted T cell therapy.